Related by context. All words. (Click for frequent words.) 71 lopinavir r arm 71 placebo dexamethasone 70 comparator arm 70 experienced virologic failure 68 oxycodone CR 67 #mg BID [001] 67 lopinavir r 66 adjunctive placebo 65 receiving VICTRELIS 65 lumbar spine BMD 65 lamivudine monotherapy 65 RGT arm 64 rimonabant #mg 64 clodronate 64 #Gy 64 mcg QD 64 #mg/day [001] 64 mg ustekinumab 64 REYATAZ r arm 64 mg Lucentis 64 QTcF 64 RLAI 64 nondiabetic patients 64 PEG Interferon alfa 64 % CI #.#-#.# [007] 64 -#.# log# 63 nadroparin 63 TMC# r 63 Peg IFN 63 #mg BID [003] 63 ALT elevation 63 5-FU/LV 63 LPV r 63 biochemical relapse 63 HbA 1c levels 63 pegylated interferon alfa 2b 63 fatigue asthenia 63 hematologic toxicity 63 CYPHER Stent 63 adjunctive ABILIFY 63 % CI #.#-#.# [003] 63 PREZISTA r arm 63 achieved ACR# 63 IFN alfa 62 log# copies mL 62 receiving ISENTRESS 62 generalized edema 62 p = NS 62 P = .# 62 infliximab monotherapy 62 REMICADE monotherapy 62 LEXIVA r 62 leukopenia 62 FOLFOX4 alone 62 mcg albinterferon alfa 2b 62 mcg BID 62 plus methotrexate 62 interferon ribavirin 62 HBeAg negative patients 62 genotype 1b 62 nonsignificant difference 62 PASI scores 62 PREZISTA ritonavir 62 mg kg dose 61 Pred Forte 61 -#.# mg dL [002] 61 #mmHg [001] 61 CI #.#-#.# [001] 61 plus OBT 61 transaminase elevations 61 zidovudine lamivudine 61 CR nPR 61 acneform rash 61 ABC/3TC 61 receiving PEGINTRON 61 atorvastatin #mg 61 Hb A1C 61 heFH 61 LAB GHRH 61 FOLFOX4 61 laboratory abnormalities 61 neutrophil counts 61 Flu Cy 61 FluCAM arm 61 virologic failure 61 p = .# [001] 61 TEAEs 61 morphometric vertebral fractures 61 rosuvastatin #mg 60 #mg QD [001] 60 Folfox 60 mg BID 60 mcg Albuferon 60 Hazard Ratio = 60 doxorubicin cyclophosphamide 60 oxycodone IR 60 iniparib BSI 60 baseline HbA1c 60 ACTEMRA TM 60 advanced adenomas 60 FOLFIRI alone 60 placebo fluoxetine 60 atazanavir ritonavir 60 dapagliflozin plus 60 pT3 60 MADRS score 60 hypophosphatemia 60 cisplatin vinorelbine 60 adefovir treated 60 mitoxantrone plus 60 % CI #.#-#.# [006] 60 unresectable HCC 60 femoral neck BMD 60 carboplatin paclitaxel 60 ug dose 60 fasting triglyceride levels 60 mg TID 60 HbA1C levels 60 HBeAg seroconversion 60 BARACLUDE ® 60 urate lowering therapy 60 p = ns 60 â ‰ ¥ 60 Viread Emtriva 60 moderate renal impairment 60 PREZISTA rtv 59 cerebrovascular events 59 BMI ≥ 59 leuprorelin 59 hypoglycemic events 59 mg qd 59 asymptomatic PAD 59 CIMZIA TM 59 aldosterone antagonist 59 stage IIIb IV 59 prednisone prednisolone 59 chronic HCV genotype 59 del 5q MDS 59 mg QD 59 mIU ml 59 dalteparin 59 achieving PASI 59 8mg/kg 59 hip BMD 59 tipranavir r 59 ritonavir boosted atazanavir 59 revascularizations 59 Engerix B 59 low dose Iluvien 59 fosamprenavir 59 PREZISTA r 59 baseline A1C 59 palmar plantar 59 umol L 59 Median PFS 59 underwent surgical resection 59 #.#/#.# mm Hg [003] 59 amoxicillin clavulanate 59 ertapenem 59 mmHg systolic 59 mcg kg REBETOL 59 binary restenosis 59 + PH# 59 arterial thromboembolic events 59 anemia hemoglobin 59 discontinuations due 59 mL/min/#.# m 2 59 recurrent VTE 59 Zometa hazard 59 ritonavir boosted lopinavir 59 NNT = 59 #mg QD [002] 59 FluCAM 59 plus dexamethasone 59 PRADAXA #mg 59 q8h 59 glycated hemoglobin levels 59 underwent CABG 59 neutropenic sepsis 58 dizziness nausea diarrhea 58 -#.# ± [002] 58 NRTI sparing 58 baseline FEV 58 COMBIVIR 58 glyburide 58 confidence interval #.#-#.# 58 EDSS score 58 pooled comparator 58 #mg dose [002] 58 tenofovir FTC 58 μg dose 58 peginterferon alfa 2b 58 prednisone prednisolone plus 58 microgram kg 58 antiretroviral naïve 58 -#.# mg dL [001] 58 nadolol 58 achieved CCyR 58 budesonide pMDI 58 normal ULN 58 nonvertebral fracture 58 zonisamide SR 58 ALT flares 58 piperacillin tazobactam 58 doxazosin 58 KRAS mutant tumors 58 leucopenia 58 EDSS scores 58 Ishak fibrosis score 58 nonobese 58 treatment naļve 58 pegylated liposomal doxorubicin 58 FOLPI 58 FOLFOX 58 Complication rates 58 ECOG PS 58 complete cytogenetic response 58 relapsed MM 58 APTIVUS r 58 tipranavir ritonavir 58 rFSH 58 HAM D# scores 58 oral antidiabetes 58 HbA1c levels 58 salmeterol fluticasone 58 Index CDAI 58 daunorubicin 58 plus gemcitabine 58 alfa 2a 58 #mg/day [002] 58 #.#ng/ml 58 oral diclofenac 58 plus GP IIb 57 severe exacerbations 57 mL/min/#.# m2 57 ropivacaine 57 tirofiban 57 mg kg Hematide 57 cells uL 57 oral allopurinol 57 systolic blood pressures 57 sustained virological response 57 pegIFN 57 PSA nadir 57 % Confidence Interval 57 abacavir lamivudine 57 3mg/kg 57 serum urate levels 57 ml kg 57 microg 57 deep venous thromboses 57 titrated glipizide plus 57 chemoradiation therapy 57 postoperative chemotherapy 57 mg BID dose 57 median CD4 57 Hazard Ratio 57 q#h 57 mild renal insufficiency 57 Fludara 57 REYATAZ r 57 Thal Dex 57 alanine aminotransferase 57 log# reduction 57 % CI #.#-#.# [008] 57 4mg/kg 57 mg + GLY 57 nonfatal MI 57 multivariable adjusted 57 NPH insulin 57 biphasic insulin aspart 57 tapentadol ER 57 CIN3 57 nonvertebral fractures 57 baseline LDH 57 suboptimal adherence 57 tertile 57 TMP SMX 57 definite stent thrombosis 57 titrated glipizide 57 pamidronate 57 genotypic resistance 57 mucositis stomatitis 57 median PFS 57 saline injections 57 virologic failures 57 preoperative chemotherapy 57 ritonavir boosted 57 femoral shaft fracture 57 coinfected 57 achieved PASI 57 telaprevir dosed 57 octreotide LAR 57 lispro 57 pg ml 57 comparator PI r 57 molindone 57 zolmitriptan 57 patients undergoing CABG 57 Operative mortality 57 pegylated interferon alpha 57 humanized interleukin 6 57 NNRTI resistance 57 glimepiride 57 methotrexate monotherapy 57 elevated transaminases 57 MMSE score 57 linaclotide treated 57 sensory neuropathy 57 adefovir 57 kBq kg 57 glycated hemoglobin HbA1c 57 severe neutropenia 57 Baseline characteristics 57 -#.# log# copies mL 57 statin monotherapy 57 hypokalemia 57 interquartile range 57 REYATAZ ritonavir 57 CrCl 56 adriamycin 56 d4T 56 virologic response 56 Viread Emtriva SUSTIVA 56 Median survival 56 echinacea tablets 56 mg kg belimumab 56 CI #.#-#.# [002] 56 events SAEs 56 clinically evaluable patients 56 ARB telmisartan 56 μg kg 56 undetectable viral 56 HBeAg negative 56 atheroma volume 56 placebo p = 56 venlafaxine XR 56 placebo p 56 TAXUS p value 56 endometrial thickness 56 cabazitaxel 56 p = #.# [002] 56 elevated serum creatinine 56 peginterferon alfa 2a 56 doxorubicin docetaxel 56 intravenous bisphosphonates 56 NMIBC 56 incidence ≥ 56 undergone splenectomy 56 argatroban 56 metformin monotherapy 56 nonmetastatic 56 salmeterol fluticasone propionate 56 severe hypoglycemic 56 patients evaluable 56 KRAS mutations occur 56 achieved mucosal healing 56 active comparator 56 kg/m2 56 plus prednisone prednisolone 56 NYHA functional class 56 NATRECOR R 56 sumatriptan naproxen sodium 56 hemoglobin A1c levels 56 #mg ATC 56 lymphopenia 56 nasopharyngitis 56 CI -#.# 56 x ULN 56 mmol l 56 squamous histology 56 timepoints 56 thromboembolic events 56 BEACOPP 56 seroconverted 56 pCR 56 #.#mg/dL 56 virological failure 56 saline placebo 56 mmHg diastolic 56 valacyclovir 56 copies ml 56 nontraumatic 56 placebo 56 hematologic adverse 56 log# IU mL 56 benazepril 56 HBeAg positive 56 receiving XGEVA 56 events AEs 56 undetectable HBV DNA 56 steroid dexamethasone 56 neurodevelopmental impairment 56 CC genotype 56 mCi m 2 56 #mg/m# [001] 56 g dl 56 lymphocyte count 56 achieved sustained virologic 56 quetiapine risperidone 56 azathioprine 56 #.#/#.# mmHg [001] 56 reinfarction 56 tamoxifen Nolvadex ® 56 nasopharyngitis headache 56 serum IGF 56 solifenacin 56 plus prednisone 56 neutropaenia 56 nevirapine Viramune 56 arthralgia 56 #mg dosing group 56 ng dL 56 extrapyramidal symptoms 56 pmol liter 56 annualized relapse 56 FFNS 56 ONGLYZA saxagliptin 56 subtrochanteric 56 bone marrow reticulin deposition 56 efavirenz EFV 56 unfractionated heparin UFH 56 chemoradiotherapy 56 mycophenolate mofetil 56 fluticasone salmeterol 56 elevated lipase 56 idraparinux 56 BMI #-#.# 56 CIMZIA TM certolizumab pegol 56 plus MTX 56 Lumbar spine 56 lopinavir 56 mg Proellex 56 oral clodronate 56 cGy 55 evaluable subjects 55 CR CRu 55 underwent liver transplantation 55 ß blockers 55 refractory ischemia 55 nondiabetics 55 GG genotype 55 NHANES III 55 unfractionated heparin 55 amprenavir 55 ATV RTV 55 intracerebral hemorrhages 55 TDF FTC 55 TPV r 55 interferon alfa 2a 55 paresthesias 55 hepatitis C genotype 55 incontinence episodes 55 postop 55 Arch Intern Med 55 indinavir 55 spine fractures 55 nelfinavir 55 recurrent glioblastoma multiforme 55 lumbar spine bone 55 preoperative PSA 55 tamsulosin 55 CCyR 55 sham injections 55 placebo Hazard Ratio 55 tenofovir emtricitabine 55 dexamethasone Decadron 55 copies mL 55 preintervention 55 virologically 55 #mg dose [003] 55 mcg kg 55 chlorthalidone 55 VELCADE melphalan 55 n = 55 confidence interval CI 55 insulin detemir 55 highest tertile 55 undergone radical prostatectomy 55 Postoperatively 55 baseline Hb 55 FUSILEV enhances 55 FDA defined valvulopathy 55 low dose cytarabine 55 mg eq 55 nicardipine 55 anthracycline taxane 55 HBeAg positive patients 55 creatinine ratio 55 tapentadol IR 55 tolterodine ER 55 MMSE scores 55 chlorambucil 55 mean baseline A1C 55 #mg q8h 55 cytogenetic abnormalities 55 multivariate adjustment 55 neutropenia dehydration dyspnea 55 Adjuvant chemotherapy 55 cyclophosphamide methotrexate 55 darunavir r 55 cilostazol 55 locoregional disease 55 HBeAg 55 mg RDEA# 55 daily subcutaneous injections 55 Infusion Reactions Severe 55 oral olanzapine 55 levosimendan 55 pg mL 55 Partial Responses 55 FOLFIRI 55 virologic breakthrough 55 adalimumab Humira 55 recurrent DVT 55 SUVmax 55 XIENCE V demonstrated 55 nondepressed 55 symptomatic VTE 55 thromboembolic 55 nonmelanoma skin cancers 55 underwent resection 55 dose cytarabine 55 β blocker 55 pmol L 55 Doxil ® 55 nucleoside naive 55 non valvular atrial 55 abdominal circumference 55 Mg Uk 55 hydroxyvitamin D levels 55 ug kg 55 mcg kg min 55 febrile neutropenia 55 serum aminotransferase levels 55 antihypertensive medications 55 LVEF 55 unboosted 55 certolizumab 55 undetectable viral load 55 rFVIIa 55 mcg linaclotide 55 sd = 55 postoperative mortality 55 paricalcitol 55 severe hypoglycaemia 55 lopinavir ritonavir Kaletra 55 receiving INTRON 55 Fasting plasma glucose 55 ACR# response 55 recurrent venous thromboembolism 55 Aptivus ® 55 elevated ALT 55 sUA levels 55 bupropion SR 55 micrograms mL 55 flutamide 55 nonpregnant women 55 #mg/kg [002] 55 microbiologically evaluable 55 underwent percutaneous coronary 55 aminotransferase elevations greater 55 tibiofemoral 55 CD4 + cell 55 nmol 55 mg m² 55 Stent thrombosis 55 postintervention 55 neuropathy sensory 55 asthenia 55 lymphocytosis 55 elevated triglyceride levels 55 deferoxamine 54 T2 lesion volume 54 #mg doses [002] 54 corticosteroid therapy 54 peginterferon alfa 54 adjuvant radiation 54 rapid virologic response 54 p = #.# [004] 54 g dL 54 μmol L 54 β blockers 54 serum creatinine levels 54 MCyR 54 oral vancomycin 54 mcg doses 54 serum triglycerides 54 Peginterferon Alfa 2a 54 ® lenalidomide 54 cells mcL 54 conventional DMARDs 54 RNA copies mL 54 UPDRS motor 54 neostigmine 54 confidence intervals CIs 54 #ug [001] 54 paclitaxel carboplatin 54 fragility fracture 54 symptomatic aortic stenosis 54 IFN beta 54 TT genotype 54 mitoxantrone 54 NIHSS 54 conjunctival hyperemia 54 neurologic complications 54 Pegylated Interferon 54 imipenem 54 acarbose 54 microbiological eradication 54 neurologic progression 54 ARCALYST ® 54 mm Hg systolic 54 sustained virologic response 54 apolipoprotein E4 54 advanced adenoma 54 VIRAMUNE 54 nmol l 54 ACR# responses 54 kg m² 54 ethambutol 54 zoledronate 54 postoperative complication 54 noncardiovascular mortality 54 aged ≥ 54 mean baseline HbA1c 54 somatostatin analog 54 stage IIIB 54 events MACE 54 #OHD levels 54 Score DAS# 54 systemic embolism 54 mg simvastatin 54 inhaled fluticasone 54 spine BMD 54 mg q#h 54 rosuvastatin Crestor 54 emtricitabine tenofovir 54 mCi kg 54 mRS 54 XELOX 54 BMS p = 54 lopinavir ritonavir 54 HIV RNA 54 nodular partial response 54 REYATAZ ® 54 nmol liter 54 invasive carcinomas 54 mg Androxal 54 non splenectomized 54 naïve HCV 54 μg liter 54 bisoprolol 54 mg/m2 dose 54 divalproex sodium 54 mineral density 54 null responder HCV 54 Cypher Stent 54 ribavirin RBV 54 pimecrolimus cream 54 aspirin clopidogrel 54 verum acupuncture 54 ribavirin therapy 54 Subgroup analysis 54 metastatic GIST 54 glargine 54 malignancy HCM 54 baseline serum creatinine 54 nonunions 54 mU liter 54 TNF antagonist 54 Apidra ® 54 systolic dysfunction 54 acromegalic patients 54 prior chemotherapy regimens 54 mild renal impairment 54 corticosteroid dose 54 heterozygotes 54 fluorouracil leucovorin 54 hypoglycaemic episodes 54 nulliparous women 54 hyperlipemia 54 peg interferon 54 Taxus Stent 54 Index CDAI score 54 thrombocytopenic 54 locoregional recurrence 54 lenalidomide dexamethasone 54 p = .# [002] 54 hepatorenal syndrome 54 poor metabolizers 54 CLL SLL 54 weekly CSBMs 54 blastic phase 54 seropositive patients 54 subcutaneous enoxaparin 54 intraabdominal 54 thiazide diuretics 54 ddI 54 Patency 54 noninferior 54 cough dyspnea 54 nondiabetic 54 QRS duration 54 lispro alone 54 statistically significant superiority 54 treated nonoperatively 54 MACCE 54 interferon alfa 54 diuretic chlorthalidone 54 headache abdominal pain 53 mEq L 53 Peginterferon 53 response CCyR 53 Crohn Disease Activity 53 ezetimibe simvastatin 53 receiving antiretroviral therapy 53 HOMA IR 53 AGILECT R 53 subcutaneous insulin 53 aminotransferases 53 log# 53 ALIMTA cisplatin 53 seroprotection 53 aspartate aminotransferase 53 AZT zidovudine Retrovir 53 fasting plasma glucose FPG 53 hydroxymethyl coenzyme 53 EUFLEXXA R 53 #.#g/day 53 aprepitant 53 pegylated interferon alfa 2a 53 mm Hg diastolic 53 intravitreal injections 53 exemestane 53 coinfected patients 53 malignant neoplasm 53 % CI #.#-#.# [005] 53 discontinuations 53 lamivudine refractory patients 53 stent thromboses 53 Durezol 53 achieved sustained virological 53 CANCIDAS 53 serum uric acid 53 elevated hsCRP 53 MBq 53 antiandrogen 53 Acetate Rectal Suppositories 53 ATACAND 53 peripheral edema 53 relapsers 53 hours postdose 53 pT2 53 NRTI 53 mg Pycnogenol 53 gm dl 53 mg tid 53 COPD exacerbation 53 headache nasopharyngitis 53 DAS# CRP 53 PHPT 53 -#.# ± [001] 53 VaD 53 ziprasidone 53 ALVESCO 53 #mg dosing 53 insulin glargine 53 adenoma recurrence 53 HbA 1c 53 Erythropoietic therapies may 53 rizatriptan 53 ± SD 53 perioperative mortality 53 highest quintile 53 refractory NSCLC 53 Lipitor #mg 53 recurrent atrial fibrillation 53 evaluating tivozanib 53 insulin lispro 53 isoproterenol 53 androgen deprivation 53 HIV HCV coinfected 53 Aspergillus infections 53 PegIFN RBV 53 docetaxel chemotherapy 53 syncopal 53 DMARD therapy 53 creatinine clearance 53 EBRT 53 Non inferiority 53 recurrent metastatic 53 uncorrected visual acuity 53 QTc prolongation 53 non vertebral fractures 53 enalapril 53 BMD measurements 53 intermittent dosing 53 mg/m2/day 53 desvenlafaxine succinate 53 receiving prophylactic anticoagulation 53 posttreatment 53 noncarriers 53 Hazard Ratio HR 53 p ≤ 53 fluticasone 53 serum folate 53 tibolone 53 mg subcutaneously 53 % CI #.#-#.# [004] 53 melphalan prednisone 53 IFN α 53 hypogonadal 53 postoperative infections 53 Kaplan Meier analysis 53 perioperative complications 53 univariate analysis 53 colorectal adenoma 53 μg doses 53 weekly subcutaneous injections 53 mg dosed twice 53 viral titers 53 biologic DMARD 53 oral antidiabetic drugs 53 PegIntron 53 #mg #mg #mg [003] 53 loop diuretics 53 rHuEPO 53 serum concentrations 53 abdominal irradiation 53 eplerenone 53 statistically significant p = 53 Fasting blood glucose 53 mg p = 53 IOP lowering 53 primary hypercholesterolemia 53 lipid lowering agents 53 R# #mg BID 53 anemia neutropenia 53 detemir 53 sulfonylurea metformin 53 TAVR 53 IRLS score 53 URTI 53 prolonged QT interval 53 gout flares 53 #.#mmol L [002] 53 posaconazole 53 biochemical recurrence 53 endometrial ovarian 53 folic acid takers 53 #OHD 53 receiving VELCADE 53 mmol liter 53 nmol L 53 QT interval prolongation 53 hip femoral neck 53 Rating Scale MADRS 53 alemtuzumab treated 53 beta carotene supplementation 53 vincristine doxorubicin 53 serum urate 53 mcg mL 53 VFEND 53 Hgb 53 mcg dose 53 hypovitaminosis D 53 DOXIL ® 53 virologically suppressed 53 oral antidiabetic medication 53 polyp recurrence 53 hormone receptor negative 53 HER2 positive tumors 53 placebo dummy pill 53 CLA supplementation 53 % CI #.#-#.# [002] 53 mRCC 53 fluorouracil 53 ALND 53 highly emetogenic 53 Clinically significant 53 p = #.# [003] 53 OADs 53 events TEAEs 53 lowest tertile 53 gout flare 53 fluvastatin 53 ximelagatran 53 clomipramine 53 retransplantation 53 adalimumab 53 ALT elevations 53 SGRQ 53 peginterferon alpha 2a 53 virological response 53 plasma HCV RNA 53 BARACLUDE r 53 % CI #.#-#.# [001] 53 apremilast 53 hypercholesterolaemia 53 XIENCE V PROMUS Stent 53 Scale EDSS 53 mg dose 53 dose atorvastatin 53 hypertension diabetes mellitus 53 degarelix 53 complete cytogenetic 53 pretreatment baseline 53 elevated troponin 52 hemoglobin A1c HbA1c 52 plasma homocysteine levels 52 symptomatic intracranial 52 μg d 52 NYHA class 52 carotid artery blockage 52 underwent radical prostatectomy 52 p = 52 PEG Intron 52 HER2 expression 52 ° preoperatively 52 ìg 52 completely resected 52 diastolic blood pressures 52 partial remissions 52 mmHg p = 52 LV dysfunction 52 Psoriasis Area 52 abnormal ejaculation 52 cisplatin chemotherapy 52 treatment naïve genotype 52 bivalirudin monotherapy 52 Avandia Actos 52 HCV genotype 52 placebo PBO 52 prior relapsers 52 DEXA scans 52 beta blocker therapy 52 telaprevir pegylated interferon 52 CDAI score 52 baseline neutrophil counts 52 hypoglycemic episodes 52 azilsartan medoxomil 52 dose colchicine 52 DAS# [002] 52 antithymocyte globulin 52 thrombocytopenia neutropenia 52 mg/# h 52 Crestor rosuvastatin 52 HbA1C 52 Kivexa 52 atrophic gastritis 52 progesterone receptor negative 52 adjuvant radiotherapy 52 remission CR 52 P ≤ 52 lifetime abstainers 52 mmol kg 52 ibandronate 52 treatment naive genotype 52 X ULN 52 intravenous cyclophosphamide 52 timepoint 52 mU L 52 atazanavir 52 advanced neoplasia 52 abacavir 52 SGOT 52 Median progression 52 ipsilateral stroke 52 haematologic 52 achieved statistical significance 52 renal flares 52 1mg dose 52 seropositivity 52 primary patency 52 Lucentis monotherapy 52 μg mL 52 concomitant antibiotics 52 inadequate glycemic 52 Toxicities 52 mg calcium 52 simvastatin ezetimibe 52 #mm Hg 52 DETROL LA 52 recurrent UTI 52 irbesartan 52 thromboembolism 52 Scale EDSS score 52 plus medroxyprogesterone acetate 52 metoprolol tartrate 52 detectable HCV RNA 52 autoantibody positive 52 Paraplatin ® 52 aspartate aminotransferase AST 52 hepatic enzymes 52 μg L 52 ‰ ¥ 52 GSK# [001] 52 myocardial infarctions